Influenza B: Prospects for the Development of Cross-Protective Vaccines

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Jun 24

PMID 35746794

Authors

Liudmila M Tsybalova

Liudmila A Stepanova

Edward S Ramsay

Andrey V Vasin

Affiliations

Soon will be listed here.

Abstract

In this review, we analyze the epidemiological and ecological features of influenza B, one of the most common and severe respiratory infections. The review presents various strategies for cross-protective influenza B vaccine development, including recombinant viruses, virus-like particles, and recombinant proteins. We provide an overview of viral proteins as cross-protective vaccine targets, along with other updated broadly protective vaccine strategies. The importance of developing such vaccines lies not only in influenza B prevention, but also in the very attractive prospect of eradicating the influenza B virus in the human population.

Citing Articles

A single mutation at position 214 of influenza B hemagglutinin enhances cross-neutralization.

Cheng Z, Sun Y, Shen Y, Wu X, Pan L, Wu H Emerg Microbes Infect. 2025; 14(1):2467770.

PMID: 39960410 PMC: 11849025. DOI: 10.1080/22221751.2025.2467770.

Genetic characterization of influenza B virus and oseltamivir resistance in pediatric patients with acute respiratory infections: a cross-sectional study.

Alizadeh S, Edalat F, Letafati A, Pirbonyeh N, Tabibzadeh A, Mousavizadeh L Virus Genes. 2024; 61(1):54-63.

PMID: 39499431 DOI: 10.1007/s11262-024-02119-x.

Influenza B Virus Vaccine Innovation through Computational Design.

Pekarek M, Weaver E Pathogens. 2024; 13(9).

PMID: 39338946 PMC: 11434669. DOI: 10.3390/pathogens13090755.

COVID-19 Vaccination Strategies in the Endemic Period: Lessons from Influenza.

Nham E, Noh J, Park O, Choi W, Song J, Cheong H Vaccines (Basel). 2024; 12(5).

PMID: 38793765 PMC: 11125835. DOI: 10.3390/vaccines12050514.

The effect of nonpharmaceutical interventions on influenza virus transmission.

Chen D, Zhang T, Chen S, Ru X, Shao Q, Ye Q Front Public Health. 2024; 12:1336077.

PMID: 38389947 PMC: 10881707. DOI: 10.3389/fpubh.2024.1336077.

References

Wohlbold T, Krammer F . In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses. 2014; 6(6):2465-94. PMC: 4074938. DOI: 10.3390/v6062465. View

Pleguezuelos O, James E, Fernandez A, Lopes V, Rosas L, Cervantes-Medina A . Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines. 2020; 5(1):22. PMC: 7069936. DOI: 10.1038/s41541-020-0174-9. View

Horimoto T, Iwatsuki-Horimoto K, Hatta M, Kawaoka Y . Influenza A viruses possessing type B hemagglutinin and neuraminidase: potential as vaccine components. Microbes Infect. 2004; 6(6):579-83. DOI: 10.1016/j.micinf.2004.02.011. View

Hatta M, Kawaoka Y . The NB protein of influenza B virus is not necessary for virus replication in vitro. J Virol. 2003; 77(10):6050-4. PMC: 154028. DOI: 10.1128/jvi.77.10.6050-6054.2003. View

Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S . A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med. 2017; 9(412). DOI: 10.1126/scitranslmed.aam5752. View

Tan Y, Guan W, Lam T, Pan S, Wu S, Zhan Y . Differing epidemiological dynamics of influenza B virus lineages in Guangzhou, southern China, 2009-2010. J Virol. 2013; 87(22):12447-56. PMC: 3807886. DOI: 10.1128/JVI.01039-13. View

Bereszczak J, Barbu I, Tan M, Xia M, Jiang X, van Duijn E . Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry. J Struct Biol. 2012; 177(2):273-82. DOI: 10.1016/j.jsb.2012.01.005. View

Glezen W, Schmier J, Kuehn C, Ryan K, Oxford J . The burden of influenza B: a structured literature review. Am J Public Health. 2013; 103(3):e43-51. PMC: 3673513. DOI: 10.2105/AJPH.2012.301137. View

de Vries R, Nieuwkoop N, van der Klis F, Koopmans M, Krammer F, Rimmelzwaan G . Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity. J Infect Dis. 2018; 217(1):3-11. PMC: 5853962. DOI: 10.1093/infdis/jix546. View

10.

Ran Z, Shen H, Lang Y, Kolb E, Turan N, Zhu L . Domestic pigs are susceptible to infection with influenza B viruses. J Virol. 2015; 89(9):4818-26. PMC: 4403465. DOI: 10.1128/JVI.00059-15. View

11.

Skowronski D, Hottes T, De Serres G, Ward B, Janjua N, Sabaiduc S . Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata. Pediatr Infect Dis J. 2011; 30(10):833-9. DOI: 10.1097/INF.0b013e31822db4dc. View

12.

Hatta M, Goto H, Kawaoka Y . Influenza B virus requires BM2 protein for replication. J Virol. 2004; 78(11):5576-83. PMC: 415801. DOI: 10.1128/JVI.78.11.5576-5583.2004. View

13.

Hayward A, Wang L, Goonetilleke N, Fragaszy E, Bermingham A, Copas A . Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med. 2015; 191(12):1422-31. PMC: 4476562. DOI: 10.1164/rccm.201411-1988OC. View

14.

Jenson H, Baltimore R . Impact of pneumococcal and influenza vaccines on otitis media. Curr Opin Pediatr. 2004; 16(1):58-60. DOI: 10.1097/00008480-200402000-00011. View

15.

Tan G, Lee P, Hoffman R, Mazel-Sanchez B, Krammer F, Leon P . Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014; 88(23):13580-92. PMC: 4248980. DOI: 10.1128/JVI.02289-14. View

16.

Puzelli S, Di Martino A, Facchini M, Fabiani C, Calzoletti L, Di Mario G . Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017. BMC Infect Dis. 2019; 19(1):990. PMC: 6873537. DOI: 10.1186/s12879-019-4621-z. View

17.

Chai N, Swem L, Park S, Nakamura G, Chiang N, Estevez A . A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017; 8:14234. PMC: 5253702. DOI: 10.1038/ncomms14234. View

18.

Ma C, Soto C, Ohigashi Y, Taylor A, Bournas V, Glawe B . Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus. J Biol Chem. 2008; 283(23):15921-31. PMC: 2414288. DOI: 10.1074/jbc.M710302200. View

19.

Skowronski D, Chambers C, De Serres G, Sabaiduc S, Winter A, Dickinson J . Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada. J Infect Dis. 2017; 216(6):697-702. PMC: 5853978. DOI: 10.1093/infdis/jix393. View

20.

Lowen A, Steel J, Mubareka S, Carnero E, Garcia-Sastre A, Palese P . Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol. 2009; 83(7):2803-18. PMC: 2655561. DOI: 10.1128/JVI.02424-08. View